U
Ultragenyx Pharmaceutical Inc. (RARE)
NMS – Real Time Price. Currency in USD
30.77
+1.52 (5.20%)
At close: Jun 26, 2026, 4:00 PM EDT
30.77
0.00 (0.00%)
After-hours: Jun 26, 2026, 6:54 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
30.77
+1.52 (5.20%)
At close: Jun 26, 2026, 4:00 PM EDT
30.77
0.00 (0.00%)
After-hours: Jun 26, 2026, 6:54 PM EDT
No Data
There are no news for this stock.
Total debt $1.2B significantly exceeds cash reserves ($183.0M), raising financial stability concerns
Total current assets $657.0M exceed Total current liabilities $325.0M, highlighting excellent liquidity
Debt-to-equity ratio (-5.2) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-8.0x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$198.0M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.02 | 6.05 | 10 | |
| Quick ratio | 1.85 | 5.63 | 9.0 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 0.93 | 1.04 | 2.0 | |
| Interest coverage | -8.05 | -16.91 | 1.0 | |
| Weighted average score | 4.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 363M | 434M | 560M | 673M | 669M |
| Gross Profit | 320M | 367M | 453M | 537M | 525M |
| Operating Income | -649M | -569M | -536M | -535M | -562M |
| Net Income | -707M | -607M | -569M | -575M | -609M |
| EBITDA | -631M | -543M | -500M | -500M | -528M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 9.15 | -4.19 | 3.5 |
| Next quarter | 14.95 | 43.3 | 9.0 |
| Current year | 10.17 | 23.11 | 8.5 |
| Next year | 32.65 | 84.4 | 10 |
| Weighted average score | 7.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -34.29 | -43.4 | -42.63 | -96.48 | 1.0 |
| Y/Y | -2.35 | -22.44 | -17.19 | -17.99 | 1.0 |
| 3y average | 22.89 | 6.47 | 16.52 | 0.77 | 6.5 |
| 5y average | 20.34 | -35.94 | -23.93 | -30.4 | 3.3 |
| Weighted average score | 3.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |